Author(s): Dhandhukiya Manavkumar Kanubhai, Saiyed Musaratafrin Sabirali

Email(s): musaratsaiyed40@gmail.com

DOI: 10.52711/2231-5659.2023.00030   

Address: Dhandhukiya Manavkumar Kanubhai*, Saiyed Musaratafrin Sabirali
Department of Pharmacology, A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, Vallabh Vidyanagar, Anand-388120. *Corresponding Author

Published In:   Volume - 13,      Issue - 2,     Year - 2023


ABSTRACT:
Hepatocellular Carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. Several risk factors responsible for development of HCC are liver and biliary Cirrhosis, Alcohol consumption, Hepatitis B and C infection, exposure to carcinogenic substance like Aflatoxin and Arsenic, comorbid condition like Obesity and Diabetes etc. In this review we discus about risk factors, screening methods and stages of HCC. Multiple treatment availability such as Radiation therapy, Chemotherapy and Surgical procedures along with newer modalities like Targeted Drug Delivery System, use of nano technology, newer Immunomodulators and Radiofrequency Ablation. Continued improvement in both surgical and nonsurgical approaches has demonstrated significant benefits in overall survival.


Cite this article:
Dhandhukiya Manavkumar Kanubhai, Saiyed Musaratafrin Sabirali. Hepatocellular Carcinoma: A Review. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(2):171-9. doi: 10.52711/2231-5659.2023.00030

Cite(Electronic):
Dhandhukiya Manavkumar Kanubhai, Saiyed Musaratafrin Sabirali. Hepatocellular Carcinoma: A Review. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(2):171-9. doi: 10.52711/2231-5659.2023.00030   Available on: https://ajpsonline.com/AbstractView.aspx?PID=2023-13-2-16


REFERENCES:
1.    Hepatocellular carcinoma - Overview - Mayo Clinic [Internet]. Mayoclinic.org. 2022 [cited 8 August 2022]. Available from: https://www.mayoclinic.org/diseases-conditions/hepatocellular-carcinoma/cdc-20354552
2.    Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014 Apr 21;20(15):4115-27. doi: 10.3748/wjg.v20.i15.4115.
3.    McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 Jan;73Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288.
4.    Acharya SK. Epidemiology of hepatocellular carcinoma in India. J ClinExpHepatol. 2014 Aug;4(Suppl 3):S27-33. doi: 10.1016/j.jceh.2014.05.013.
5.    Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25(2):143-54. doi: 10.1055/s-2005-871194.
6.    Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
7.    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013 Jul;58(1):98-107. doi: 10.1002/hep.26180.
8.    Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. SurgClin North Am. 2013 Dec;93(6):1423-50. doi: 10.1016/j.suc.2013.08.008.
9.    Lok AS, SeeffLB, Morgan TR, et.al. incidence of hepatocellular carcinoma and associated risk factor in hepatitis C- related advanced liver disease. Gastroenterology2009;136(1):138-148.
10.    International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Alcohol 1998;44(44):207–215.
11.    Batey RG, Burns T, Benson RJ, Byth K. Alcohol consumption and the risk of cirrhosis. Med J Aust. 1992 Mar 16;156(6):413-6. doi: 10.5694/j.1326-5377.1992.tb139846.x.
12.    Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev. 1998 Apr;7(2):89-107.
13.    Balkau B, Kahn HS, Courbon D, Eschwège E, Ducimetière P; Paris Prospective Study. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care. 2001 May;24(5):843-9. doi: 10.2337/diacare.24.5.843.
14.    Yuan JM, Ross RK, Stanczyk FZ, Govindarajan S, Gao YT, Henderson BE, Yu MC. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer. 1995 Nov 15;63(4):491-3. doi: 10.1002/ijc.2910630405.
15.    White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012 Mar;55(3):759-68. doi: 10.1002/hep.24618. Epub 2011 Dec 14.
16.    hen JG, Egner PA, Ng D, Jacobson LP, Muñoz A, Zhu YR, Qian GS, Wu F, Yuan JM, Groopman JD, Kensler TW. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila). 2013 Oct;6(10):1038-45. doi: 10.1158/1940-6207.CAPR-13-0168.
17.    Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006 Sep;6(9):674-87. doi: 10.1038/nrc1934.
18.    Riley J, Mandel HG, Sinha S, Judah DJ, Neal GE. In vitro activation of the human Harvey-ras proto-oncogene by aflatoxin B1. Carcinogenesis. 1997 May;18(5):905-10. doi: 10.1093/carcin/18.5.905.
19.    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65-73. doi: 10.1001/jama.295.1.65.
20.    Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003 Aug 11;22(33):5093-107. doi: 10.1038/sj.onc.1206557.
21.    Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002 May;27(1):63-8. doi: 10.1016/s0741-8329(02)00215-x.
1.    Fayed, L. (n.d.). Symptoms of liver cancer. Verywell Health. Retrieved September 10, 2021, from https://www.verywellhealth.com/liver-cancer-symptoms-514170.
22.    Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? HepatobiliarySurgNutr. 2014 Dec;3(6):410-4. doi: 10.3978/j.issn.2304-3881.2014.07.06.
23.    Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015 Feb 27;7(2):139-49. doi: 10.4254/wjh.v7.i2.139.
24.    Omata, M., Cheng, AL., Kokudo, N. et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 11, 317–370 (2017). doi: 10.1007/s12072-017-9799-9.
25.    Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003 May;37(5):1114-21. doi: 10.1053/jhep.2003.50195.
26.    Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol. 2014 Mar;49(3):555-63. doi: 10.1007/s00535-013-0883-1.
27.    Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res ClinOncol. 2013 Aug;139(8):1417-24. doi: 10.1007/s00432-013-1458-5.
28.    Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003 Jan;37(1):198-207. doi: 10.1053/jhep.2003.50022.
29.    Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, Chen F, Xia H, Lv F, Zhang S, Sun L. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLoS One. 2016 Mar 15;11(3):e0151501. doi: 10.1371/journal.pone.0151501.
30.    Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005 Dec;43(6):1007-12. doi: 10.1016/j.jhep.2005.05.028.
31.    Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012 Feb;55(2):483-90. doi: 10.1002/hep.24703.
32.    Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V, Giacomin A, Pontisso P, Cillo U, Farinati F. Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). J GastroenterolHepatol. 2014 Aug;29(8):1637-44. doi: 10.1111/jgh.12576.
33.    Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang Y, Lin K, Ma S, Yang X, Qian X, Zhao X. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis. 2013 Mar;34(3):595-604. doi: 10.1093/carcin/bgs372.
34.    Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res. 2015 Jan;45(2):128-41. doi: 10.1111/hepr.12386.
35.    Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al, FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. Science. 2005 Sep 2;309(5740):1559-63. doi: 10.1126/science.1112014.
36.    Sun J, Bie B, Zhang S, Yang J, Li Z. Long non-coding RNAs: critical players in hepatocellular carcinoma. Int J Mol Sci. 2014 Nov 7;15(11):20434-48. doi: 10.3390/ijms151120434.
37.    Sun C, Liao W, Deng Z, Li E, Feng Q, Lei J, Yuan R, Zou S, Mao Y, Shao J, Wu L, Zhang C. The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2017 Jul;96(29):e7513. doi: 10.1097/MD.0000000000007513.
38.    García-Olmo DC, Domínguez C, García-Arranz M, Anker P, Stroun M, García-Verdugo JM, García-Olmo D. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010 Jan 15;70(2):560-7. doi: 10.1158/0008-5472.
39.    Liver Cancer - Types of Treatment [Internet]. Cancer.Net. 2022 [cited 23 September 2021]. Available from: https://www.cancer.net/cancer-types/liver-cancer/types-treatment
40.    Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.
41.    Tests [Internet]. Cancer Council NSW. 2022 [cited 15 September 2021]. Available from: https://www.cancercouncil.com.au/liver-cancer-secondary/diagnosis/tests/#PET-CT
42.    Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7(1):35-41. doi: 10.1080/13651820410024058.
43.    Keliher EJ, Reiner T, Earley S, Klubnick J, Tassa C, Lee AJ, et al; Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia. 2013 Jul;15(7):684-93. doi: 10.1593/neo.13276.
44.    Cancer Staging [Internet]. National Cancer Institute. 2022 [cited 29 September 2021]. Available from: https://www.cancer.gov/about-cancer/diagnosis-staging/staging
45.    Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002 May;122(6):1609-19. doi: 10.1053/gast.2002.33411.
46.    Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Dao T, et al; Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998 Jul;29(1):129-34. doi: 10.1016/s0168-8278(98)80187-6.
47.    Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al; A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8. doi: 10.1097/01.sla.0000201480.65519.b8.
48.    Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al; A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012 Oct;57(4):794-802. doi: 10.1016/j.jhep.2012.05.007.
49.    Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009 Feb;49(2):453-9. doi: 10.1002/hep.22648.
50.    Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, et al; Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002 May;223(2):331-7. doi: 10.1148/radiol.2232010775.
51.    Di Vece F, Tombesi P, Ermili F, Maraldi C, Sartori S. Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: a prospective pilot study. CardiovascInterventRadiol. 2014 Jun;37(3):723-9. doi: 10.1007/s00270-013-0733-9.
52.    Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014 Aug;260(2):329-40. doi: 10.1097/SLA.0000000000000236.
53.    Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann SurgOncol. 2010 Aug;17(8):2073-80. doi: 10.1245/s10434-010-0940-4.
54.    Li XL, Zhu XD, Cai H, Li Y, Zhou J, Fan J, et al; Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. Surgery. 2019 Jun;165(6):1161-1167. doi: 10.1016/j.surg.2019.01.009.
55.    Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl. 2018 Mar;24(3):369-379. doi: 10.1002/lt.24977.
56.    Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol. 2018 Dec 7;24(45):5081-5094. doi: 10.3748/wjg.v24.i45.5081.
57.    Recent advances in bionanomaterials for liver cancer diagnosis and treatment [Internet].  2021[cited 29 September 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/34032223/
58.    Indranil Singh. A Review on in-Vivo Imaging of Cancer Cells by Bioconjugated Quantum Dots. Asian J. Pharm. Res. 2018; 8(4): 243-248. doi: 10.5958/2231-5691.2018.00042.4
59.    Kalyankar T. M., Butle S. R., Chamwad G. N. Application of Nanotechnology in Cancer Treatment. Research J. Pharm. and Tech. 5(9): September 2012; Page 1161-1167.
60.    Qi X, Lam SS, Liu D, Kim DY, Ma L, Alleruzzo L, et al; Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol. 2016 Aug;7(4):438. doi: 10.4172/2155-9899.1000438.
61.    Avinash B. Thalkari, Pawan N. Karwa, Priyanka S. Chopane, Nareshkumar R. Jaiswal. Nanotechnology: The Future of Cancer. Asian J. Pharm. Tech. 2019; 9(1):40-48. doi: 10.5958/2231-5713.2019.00008.4
62.    Rahul Krishnan P R, Sivakumar R. Nanotechnology: Modern Formulation and Evaluation Techniques - An Overview. Research J. Pharm. and Tech 2019; 12(8): 4039-4044. doi: 10.5958/0974-360X.2019.00696.6
63.    DibyajyotiSaha, TarashankarMaity, Mayukh Jana, SupradipMandal. Cancer Treatment Strategy-An Overview. Asian J. Pharm. Tech. 1(2): April-June 2011; Page 28-33.
64.    KumbharSwapnil, Salunkhe Vijay, MagdumChandrakant. Targeted Drug Delivery: A Backbone for Cancer Therapy. Asian J. Pharm. Res. 3(1): Jan.-Mar. 2013; Page 40-46.
65.    Cai XR, Li X, Lin JX, Wang TT, Dong M, Chen ZH, Jia CC, Hong YF, Lin Q, Wu XY. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review. Oncotarget. 2017 May 9;8(19):31318-31328. doi: 10.18632/oncotarget.15454.
66.    Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J ClinOncol. 2018 Feb 1;48(2):103-114. doi: 10.1093/jjco/hyx180.
67.    Kuol N, Stojanovska L, Nurgali K, Apostolopoulos V. PD-1/PD-L1 in disease. Immunotherapy. 2018 Feb;10(2):149-160. doi: 10.2217/imt-2017-0120.
68.    Cheng H, Sun G, Chen H, Li Y, Han Z, Li Y, et al; Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019 Aug 1;9(8):1536-1545.
69.    Doherty DG. Immunity, tolerance and autoimmunity in the liver: A comprehensive review. J Autoimmun. 2016 Jan;66:60-75. doi: 10.1016/j.jaut.2015.08.020.

Recomonded Articles:

Author(s): Saurabh Tiwari, Shweta Singh, Pushpendra Kumar Tripathi, Chetan Kumar Dubey

DOI: 10.5958/2231-5659.2015.00037.5         Access: Open Access Read More

Author(s): Pooja M. Nikam, S.B. Gondkar, R.B. Saudagar

DOI: 10.5958/2231-5659.2015.00036.3         Access: Open Access Read More

Author(s): Neha Jasrotia, Bharat Prashar

DOI:         Access: Open Access Read More

Author(s): Vignesh Balaji E, Tamil Selvan A

DOI: 10.5958/2231-5659.2019.00003.1         Access: Open Access Read More

Author(s): Somsubhra Ghosh, Sowjanya Bomma, V. Laxmi Prasanna, P. Srivani, David Bhanji

DOI:         Access: Open Access Read More

Author(s): Merlin N.J., Shaji Selvin, Sukesh T.N.

DOI:         Access: Open Access Read More

Author(s): Sarika V. Khandbahale, R. B. Saudagar

DOI: 10.5958/2231-5659.2017.00026.1         Access: Open Access Read More

Author(s): Pagar Swati A., Suryawanshi Hemant K.

DOI: 10.5958/2231-5659.2021.00011.4         Access: Open Access Read More

Author(s): Sirisha, Praveena R.

DOI: 10.5958/2231-5659.2020.00038.7         Access: Open Access Read More

Author(s): Kiran Patole, Anil Danane, Amit Nikam, Anuja Patil

DOI: 10.52711/2231-5659.2021.00050         Access: Open Access Read More

Author(s): Sanjay S. Patel, Poojan N. Patel

DOI: 10.52711/2231-5659.2023.00004         Access: Closed Access Read More

Author(s): Sable Akash, Jadhav S.L., Kamble S.C.

DOI: 10.52711/2231-5659.2022.00034         Access: Closed Access Read More

Author(s): Sushma. NC, J Adlin Jino Nesalin, E. Gopinath, Vineeth Chandy

DOI: 10.52711/2231-5659.2023.00043         Access: Closed Access Read More

Author(s): Vidya Ashok Kheradkar, Jameel Ahmed S. Mulla

DOI: 10.52711/2231-5659.2023.00020         Access: Closed Access Read More

Author(s): Dhandhukiya Manavkumar Kanubhai, Saiyed Musaratafrin Sabirali

DOI: 10.52711/2231-5659.2023.00030         Access: Closed Access Read More

Author(s): Sourabh D. Jain, Anuja Awasthi, Arun K. Gupta

DOI: 10.52711/2231-5659.2024.00008         Access: Closed Access Read More

Asian Journal of Research in Pharmaceutical Sciences (AJPSci) is an international, peer-reviewed journal, devoted to pharmaceutical sciences....... Read more >>>

RNI: Not Available                     
DOI: 10.52711/2231-5659 


Recent Articles




Tags